Where should the drug industry go to find new ideas? In the first of two features, Alison Abbott asked if the future lies in systems biology -- a field that attempts to piece together 'everything'. In this, the second feature, David Cyranoski looks at drug companies' attraction to China.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Additional information
David Cyranoski is Nature's Asia Pacific correspondent.
Related links
Related links
Related links in Nature Research
Related external links
Rights and permissions
About this article
Cite this article
Cyranoski, D. Pharmaceutical futures: Made in China?. Nature 455, 1168–1170 (2008). https://doi.org/10.1038/4551168a
Published:
Issue Date:
DOI: https://doi.org/10.1038/4551168a
This article is cited by
-
China, Globalisation and Health Biotechnology Innovation: Venture Capital and the Adaptive State
East Asian Science, Technology and Society: an International Journal (2009)
